Can-Fite BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.53	4.83	4.28	2.98	4.39
Short-Term Investments	3.01	3.06	4.64	5	14.51
Trading Asset Securities	-	-	-	0.01	0.24
Cash & Short-Term Investments	8.54	7.89	8.92	7.99	19.14
Cash Growth	8.28%	-11.60%	11.71%	-58.27%	129.40%
Prepaid Expenses	0.83	1.02	0.91	1.12	0.88
Other Current Assets	0.07	0.08	0.08	0.05	0.05
Total Current Assets	9.44	8.98	9.91	9.16	20.07
Property, Plant & Equipment	0.07	0.14	0.08	0.13	0.19
Total Assets	9.51	9.12	9.99	9.28	20.25
Accounts Payable	1.16	0.62	0.43	0.9	0.95
Accrued Expenses	1.11	0.98	0.94	0.78	0.91
Current Portion of Leases	0.06	0.05	0.03	0.05	0.05
Current Unearned Revenue	0.41	0.41	0.62	0.78	0.82
Total Current Liabilities	2.73	2.05	2.02	2.5	2.73
Long-Term Leases	0.02	0.05	0.01	0.01	0.07
Long-Term Unearned Revenue	1.18	1.58	1.71	2.3	3.07
Total Liabilities	3.92	3.68	3.75	4.81	5.87
Additional Paid-In Capital	180.65	170.67	163.6	154.19	153.93
Retained Earnings	-176.19	-166.36	-158.48	-150.85	-140.67
Comprehensive Income & Other	1.13	1.13	1.13	1.13	1.13
Total Common Equity	5.59	5.44	6.24	4.47	14.38
Shareholders' Equity	5.59	5.44	6.24	4.47	14.38
Total Liabilities & Equity	9.51	9.12	9.99	9.28	20.25
Total Debt	0.07	0.1	0.04	0.06	0.12
Net Cash (Debt)	8.47	7.78	8.88	7.93	19.02
Net Cash Growth	8.81%	-12.37%	12.08%	-58.32%	129.76%
Net Cash Per Share	5.14	10.73	20.84	29.15	103.14
Filing Date Shares Outstanding	4.29	1.04	0.5	0.41	0.27
Total Common Shares Outstanding	2.62	0.99	0.45	0.27	0.27
Working Capital	6.71	6.93	7.89	6.66	17.34
Book Value Per Share	2.14	5.47	13.77	16.45	52.89
Tangible Book Value	5.59	5.44	6.24	4.47	14.38
Tangible Book Value Per Share	2.14	5.47	13.77	16.45	52.89
Machinery	0.02	0.08	0.28	0.28	0.27
Leasehold Improvements	-	-	0.01	0.01	0.01